All Articles

Data from the TRACERx lung study suggest that circulating tumor DNA (ctDNA) may be a biomarker for the detection of postsurgical minimal residual disease (MRD) in patients with non–small-cell lung cancer (NSCLC), suggesting which patients are at higher risk of relapse and require more aggressive adjuvant therapy.

Exploring second opinions allows patients to become more informed and secure in their choice of which treatment to pursue.

A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma.

The first off-the-shelf chimeric antigen receptor (CAR) T-cell platform targeting CD7 induced a complete response (CR) with no minimal residual disease (MRD) in 4 of the first 5 adults with adult relapsed/ refractory T-cell acute lymphoblastic leukemia (T-ALL) who were treated with the universal CAR T-cell therapy known as GC027.

The combination of the checkpoint inhibitor durvalumab, the PARP inhibitor olaparib, and the taxane paclitaxel as neoadjuvant therapy improved pathological complete response (pCR) compared with physician’s choice of chemotherapy in high-risk HER2-negative stage II or III breast cancer.

The combination of the checkpoint inhibitor atezolizumab plus the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib improved progression-free survival (PFS) and lengthened duration of responses compared with the 2 targeted therapies plus placebo in newly diagnosed BRAF V600E/K–mutant advanced melanoma, according to results of the phase 3 IMspire150 trial presented at the 2020 virtual meeting of the American Association for Cancer Research.

The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce the launch of a national committee addressing community outreach, prevention, and early detection.

The Academy of Oncology Nurse & Patient Navigators (AONN+) has heard from many of its members working on the front lines of cancer care about the impact of COVID-19 on their practice.